Reslizumab
- Generic Name
- Reslizumab
- Brand Names
- Cinqair, Cinqaero
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 241473-69-8
- Unique Ingredient Identifier
- 35A26E427H
- Background
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils . Elevated levels of eosinophi...
- Indication
Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
- Associated Conditions
- Severe Eosinophilic Asthma
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 489
- Registration Number
- NCT01287039
- Locations
- 🇺🇸
Teva Investigational Site 61, Los Angeles, California, United States
🇺🇸Teva Investigational Site 51, Boston, Massachusetts, United States
🇵🇱Teva Investigational Site 500, Ostrow Wielkopolski, Poland
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 464
- Registration Number
- NCT01285323
- Locations
- 🇩🇪
Teva Investigational Site 361, Berlin, Germany
🇬🇷Teva Investigational Site 382, Heraklion, Crete, Greece
🇺🇸Teva Investigational Site 69, El Paso, Texas, United States
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT01270464
- Locations
- 🇺🇸
Teva Investigational Site 16, Fort Worth, Texas, United States
🇦🇷Teva Investigational Site 127, Ciudad Autonoma de Buenos Aire, Argentina
🇦🇷Teva Investigational Site 123, Rosario-Santa Fe, Argentina
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2022-01-27
- Target Recruit Count
- 31
- Registration Number
- NCT01111305
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Ception Therapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT00635089
- Locations
- 🇺🇸
Children's Center for Digestive Health Care, Atlanta, Georgia, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.